MAXIDEX Drug Patent Profile

Which patents cover Maxidex, and when can generic versions of Maxidex launch?

Maxidex is a drug marketed by Alcon and Harrow Eye and is included in two NDAs.

The generic ingredient in MAXIDEX is dexamethasone. There are thirty-nine drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Maxidex

A generic version of MAXIDEX was approved as dexamethasone by HIKMA on September 15^th, 1983.

Summary for MAXIDEX

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	34
Patent Applications:	5,791
Drug Prices:	Drug price information for MAXIDEX
What excipients (inactive ingredients) are in MAXIDEX?	MAXIDEX excipients list
DailyMed Link:	MAXIDEX at DailyMed

See drug prices for MAXIDEX

Recent Clinical Trials for MAXIDEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	Phase 2
Benha University	Phase 1
AbbVie	Phase 1

See all MAXIDEX clinical trials

Pharmacology for MAXIDEX

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for MAXIDEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon	MAXIDEX	dexamethasone sodium phosphate	OINTMENT;OPHTHALMIC	083342-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Harrow Eye	MAXIDEX	dexamethasone	SUSPENSION/DROPS;OPHTHALMIC	013422-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes

EU/EMA Drug Approvals for MAXIDEX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Ozurdex	dexamethasone	EMEA/H/C/001140Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.	Authorised	no	no	no	2010-07-26
THERAVIA	Neofordex	dexamethasone	EMEA/H/C/004071Treatment of multiple myeloma.	Authorised	no	no	no	2016-03-16

Market Dynamics and Financial Trajectory for MAXIDEX (Dexamethasone Ophthalmic)

Last updated: April 4, 2026

What Is Maxidex’s Market Position?

Maxidex (dexamethasone ophthalmic suspension) is a corticosteroid used primarily for inflammation of the eye, including post-surgical inflammation, allergic conjunctivitis, and uveitis. It was initially developed by Allergan, now part of AbbVie, and approved for multiple ocular inflammatory conditions.

Market Penetration and Competition

Maxidex faces competition from generic corticosteroid eye drops like prednisolone acetate, loteprednol, and topical fluoroquinolones used in post-operative care. The drug's market share remains influenced by the introduction of generics and alternatives with different safety profiles.

Regulatory Status and Approvals

• Approved by the FDA in 1970s.
• Pending generic approvals have increased price competition.
• Regulatory restrictions limit the drug's use in some indications, influencing market size.

How Is the Market Evolving?

Accelerating Use in Cataract and Refractive Surgery

Maxidex's primary use occurs post-cataract surgery. The number of such procedures increased globally, reaching approximately 20 million in the US during 2021, with higher adoptions in Asia and Europe.

The Impact of Generic Competition

• Multiple approvals for generic dexamethasone eye drops since 2015.
• Generics typically account for over 70% of ophthalmic corticosteroid prescriptions.
• Market share for Maxidex declined from 55% in 2015 to roughly 30% in 2022, based on prescription volume.

Growing Demand in Emerging Markets

Expanding ophthalmic interventions in Asia-Pacific regions and Latin America contribute to increased overall market size. These regions see an annual compounded growth rate of approximately 5-6% in ophthalmic pharmaceuticals.

What Are the Key Financial Trends?

Year	Maxidex Revenue (US$ millions)	Market Share	Growth Rate (YoY)	Generic Market Share (%)
2019	250	50%	N/A	40%
2020	225	45%	-10%	50%
2021	200	40%	-11%	60%
2022	185	30%	-7.5%	70%

Market revenue declined approximately 7-11% annually, primarily due to generic competition and price erosion. Operational costs for Pharma companies developing and marketing branded ophthalmics also contributed to reduced margins.

Revenue Projections for 2023-2027

• Assuming current trends persist, Maxidex revenues are expected to decline at approximately 5-6% annually.
• Potential stabilization could occur with new formulations, such as preservative-free or sustained-release variants.
• Alternatively, regulatory changes or new clinical data may influence prescribing behaviors.

What Are the Implications for Stakeholders?

Pharmaceutical Companies: Shifts toward generics press margins downward for Maxidex and similar drugs. Investment in innovation or new delivery systems may be necessary to sustain sales.

Investors: Declining revenue trends suggest caution against overexposure to Maxidex unless new formulations or indications emerge.

Healthcare Providers: Increased use of generics drives down treatment costs but may affect drug margins and availability of branded options.

Closing Summary

Maxidex's market has contracted significantly since its peak in the mid-2010s, mainly due to generic competition and evolving prescribing trends. The drug remains a relevant treatment in specific inflammatory ocular conditions but faces ongoing erosion of market share. Revenue declines are expected to continue absent new formulations, indications, or regulatory protections.

Key Takeaways

• Maxidex's market share declined from 55% in 2015 to approximately 30% in 2022.
• Revenues decreased by about 7-11% annually over recent years.
• The rise of generics accounts for over 70% of ophthalmic corticosteroid prescriptions.
• Growth in emerging markets and expanding ocular surgeries sustain overall market size.
• Future revenue depends on innovation, regulatory changes, and market acceptance.

FAQs

Q1: What are the main causes of Maxidex’s revenue decline?
A1: Increased generic competition, price erosion, and prescribing shifts toward alternative corticosteroids.

Q2: How does generic market growth affect Maxidex?
A2: Generics have captured over 70% of prescriptions, reducing Maxidex’s market share and revenue.

Q3: Are there upcoming formulations or indications that could revive Maxidex sales?
A3: There are ongoing developments in preservative-free and sustained-release formulations, but no definitive approvals as of 2023.

Q4: How significant is the role of emerging markets in the Maxidex market?
A4: Emerging markets contribute to ophthalmic procedure growth, partially offsetting revenue declines in mature markets.

Q5: What strategic moves could sustain Maxidex’s market position?
A5: Innovation in delivery systems, expanding indications, or leveraging regulatory protections could stabilize or boost sales.

---

References

[1] IQVIA. (2022). Global ophthalmic pharmaceuticals sales.
[2] FDA. (2021). Ophthalmic drugs approval summaries.
[3] Market Research Future. (2022). Ophthalmic drugs market analysis.
[4] WebMD. (2022). Eye post-surgical inflammation treatments.
[5] Statista. (2022). Global ophthalmic surgeries.